ArticleNature communications2023
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- Structural T-Cell Receptor Analysis in the Age of Machine Learning.Immunological reviews · 2026Review
- Structural mechanism of anti-MHC-I antibody blocking of inhibitory NK cell receptors in tumor immunity.Communications biology · 2026Article
- Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements.The Journal of clinical investigation · 2026Article
- Protein engineering: status report.Protein engineering, design & selection : PEDS · 2026Review
- Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation.Cell reports. Medicine · 2025Article
- Structure guided analysis of KRAS G12 mutants in HLA-A*11:01 reveals a length encoded immunogenic advantage in G12D.Communications biology · 2025Article
- Structural mechanism of anti-MHC-I antibody blocking of inhibitory NK cell receptors in tumor immunity.Research square · 2025Article
- Targeting peptide antigens using a multiallelic MHC I-binding system.Nature biotechnology · 2025Article
- Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.Chinese medical journal · 2025Review
- De novo design and structure of a peptide-centric TCR mimic binding module.Science (New York, N.Y.) · 2025Article
- Structural biology at the National Synchrotron Light Source II.Journal of synchrotron radiation · 2025Article
- Integrating antigen capturing nanoparticles and type 1 conventional dendritic cell therapy for in situ cancer immunization.Nature communications · 2025Article
- Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint inhibitor therapy in melanoma patients: a retrospective cohort study.BMC cancer · 2025Article
- TumorAgDB1.0: tumor neoantigen database platform.Database : the journal of biological databases and curation · 2025Article
- Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C-MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies.Cancer research · 2025Article
- Accurate quantum-centric simulations of intermolecular interactions.Communications physics · 2025Article
- Review
- Cancer therapy with antibodies.Nature reviews. Cancer · 2024Review
- An immunogenetic basis for lung cancer risk.Science (New York, N.Y.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 2 countries.
Katharine M Wright *Department of Biophysics and Biophysical Chemistry, The Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA.
Sarah R DiNapoli *Howard Hughes Medical Institute, Chevy Chase, MD, 20815, USA.ORCID http://orcid.org/0000-0002-3675-9030
Michelle S Miller *Department of Biophysics and Biophysical Chemistry, The Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA.ORCID http://orcid.org/0000-0003-1972-4503
P Aitana AzurmendiDepartment of Biophysics and Biophysical Chemistry, The Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA.
Xiaowei ZhaoJanelia Research Campus, HHMI,19700 Helix Drive, Ashburn, VA, 20147, USA.
Zhiheng YuJanelia Research Campus, HHMI,19700 Helix Drive, Ashburn, VA, 20147, USA.
Mayukh ChakrabartiDepartment of Biophysics and Biophysical Chemistry, The Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA.ORCID http://orcid.org/0000-0003-2653-9728
WuXian ShiEnergy & Photon Sciences Directorate, Brookhaven National Laboratory, Upton, NY, 11973, USA.
Jacqueline DouglassHoward Hughes Medical Institute, Chevy Chase, MD, 20815, USA.
Michael S HwangHoward Hughes Medical Institute, Chevy Chase, MD, 20815, USA.
Emily Han-Chung HsiueHoward Hughes Medical Institute, Chevy Chase, MD, 20815, USA.
Brian J MogHoward Hughes Medical Institute, Chevy Chase, MD, 20815, USA.ORCID http://orcid.org/0000-0001-9988-7147
Alexander H PearlmanHoward Hughes Medical Institute, Chevy Chase, MD, 20815, USA.ORCID http://orcid.org/0000-0002-3504-7517
Suman PaulLudwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.ORCID http://orcid.org/0000-0001-9357-3702
Maximilian F KonigHoward Hughes Medical Institute, Chevy Chase, MD, 20815, USA.ORCID http://orcid.org/0000-0001-5045-5255
Drew M PardollBloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21287, USA.
Chetan BettegowdaLudwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.ORCID http://orcid.org/0000-0001-9991-7123
Nickolas PapadopoulosLudwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.ORCID http://orcid.org/0000-0001-7135-7451
Kenneth W KinzlerBloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21287, USA.
Bert VogelsteinHoward Hughes Medical Institute, Chevy Chase, MD, 20815, USA.ORCID http://orcid.org/0000-0003-0766-3854
Shibin ZhouBloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, 21287, USA. sbzhou@jhmi.edu.ORCID http://orcid.org/0000-0003-1941-4425
Sandra B GabelliDepartment of Biophysics and Biophysical Chemistry, The Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA. Sandra.gabelli@merck.com.ORCID http://orcid.org/0000-0003-1205-5204
Bloomberg (United States) · USHoward Hughes Medical Institute · USJohns Hopkins University · USJanelia Research Campus · USBrookhaven National Laboratory · USMerck & Co., Inc., Rahway, NJ, USA (United States) · US
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6MTissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI Louis M Weiner · 1990 to 2026
$71.5MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2MLife Science and Biomedical technology Research center at NSLS-II LSBRP41GM111244 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI MCSWEENEY, SEAN · 2014 to 2018
$16.4MMedical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4MMultidisciplinary Rheumatology Training ProgramT32AR048522 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CLIFTON O BINGHAM, LIVIA A CASCIOLA-ROSEN · 2003 to 2026
$6.4MInterrogating malignant gliomas using released tumor DNA in cerebrospinal fluidR37CA230400 · NCI · JOHNS HOPKINS UNIVERSITY · PI BETTEGOWDA, CHETAN · 2018 to 2024
$2.6MTCR Targeting Antibodies for the Treatment of T cell CancersK08CA270403 · NCI · JOHNS HOPKINS UNIVERSITY · PI Suman Paul · 2022 to 2026
$1.1MNCI NIH HHS K08 CA270403NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA051008NCI NIH HHS R37 CA230400NIAMS NIH HHS T32 AR048522NIGMS NIH HHS P41 GM111244NIGMS NIH HHS T32 GM007309NIGMS NIH HHS T32 GM136577
Abstract
Specificity remains a major challenge to current therapeutic strategies for cancer. Mutation associated neoantigens (MANAs) are products of genetic alterations, making them highly specific therapeutic targets. MANAs are HLA-presented (pHLA) peptides derived from intracellular mutant proteins that are otherwise inaccessible to antibody-based therapeutics. Here, we describe the cryo-EM structure of an antibody-MANA pHLA complex. Specifically, we determine a TCR mimic (TCRm) antibody bound to its MANA target, the KRAS
Indexed as
AntibodiesProto-Oncogene Proteins p21(ras)HLA-A AntigensHydrophobic and Hydrophilic InteractionsRecognition, PsychologyAntibodiesHLA-A AntigensProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.